Evidence map›Paper›PMID 37109046›Full record

ArticleJournal of personalized medicine2023

Elucidating the Potential Inhibitor against Type 2 Diabetes Mellitus Associated Gene of GLUT4.

Afaf Aldahish, Prasanalakshmi Balaji, Rajalakshimi Vasudevan, Geetha Kandasamy, Jainey P James, Kousalya Prabahar

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. ADMET & DMPK · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Afaf AldahishDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia.ORCID 0000-0002-5073-2088
Prasanalakshmi BalajiDepartment of Computer Science, King Khalid University, Abha 61421, Saudi Arabia.ORCID 0000-0002-6882-2233
Rajalakshimi VasudevanDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia.
Geetha KandasamyDepartment of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.ORCID 0000-0002-1552-7978
Jainey P JamesDepartment of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Deralakatte, Mangaluru 575018, Karnataka, India.ORCID 0000-0002-0564-8506
Kousalya PrabaharDepartment of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.ORCID 0000-0001-8224-4276
King Khalid University · SANitte University · INUniversity of Tabuk · SA

Funding

Deanship of Scientific Research - King Khalid University RGP.2/121/43/1443H
6 · The paper itself

Abstract

Diabetes is a chronic hyperglycemic disorder that leads to a group of metabolic diseases. This condition of chronic hyperglycemia is caused by abnormal insulin levels. The impact of hyperglycemia on the human vascular tree is the leading cause of disease and death in type 1 and type 2 diabetes. People with type 2 diabetes mellitus (T2DM) have abnormal secretion as well as the action of insulin. Type 2 (non-insulin-dependent) diabetes is caused by a combination of genetic factors associated with decreased insulin production, insulin resistance, and environmental conditions. These conditions include overeating, lack of exercise, obesity, and aging. Glucose transport limits the rate of dietary glucose used by fat and muscle. The glucose transporter GLUT4 is kept intracellular and sorted dynamically, and GLUT4 translocation or insulin-regulated vesicular traffic distributes it to the plasma membrane. Different chemical compounds have antidiabetic properties. The complexity, metabolism, digestion, and interaction of these chemical compounds make it difficult to understand and apply them to reduce chronic inflammation and thus prevent chronic disease. In this study, we have applied a virtual screening approach to screen the most suitable and drug-able chemical compounds to be used as potential drug targets against T2DM. We have found that out of 5000 chemical compounds that we have analyzed, only two are known to be more effective as per our experiments based upon molecular docking studies and virtual screening through Lipinski's rule and ADMET properties.

Indexed as

ADMETChEMBLCoFACTORGLUT4MOET2DM

Identifiers

PMID37109046
PMCPMC10146764
OpenAlexW4365452883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.